Rockwell Medical Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Rockwell Medical Inc.
Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
Keeping Track: A Busy Week For Regenerative Medicine, A Surprise Priority Review For Vascepa, And Tazemetostat Aims For Accelerated Approval
The latest drug development news and highlights from our US FDA Performance Tracker.
October has not been kind to biotech stocks, but that hasn't stopped drug developers from launching IPOs in the US. Also, Takeda reconfigures debt ahead of Shire deal and other offerings.
- Medical Devices
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.